CRISPRed Macrophages for Cell-Based Cancer Immunotherapy
- 3 January 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 29 (2) , 445-450
Abstract
We present here an integrated nanotechnology/biology strategy for cancer immunotherapy that uses arginine nanoparticles (ArgNPs) to deliver CRISPR-Cas9 gene editing machinery into cells to generate SIRP-α knockout macrophages. The NP system efficiently codelivers single guide RNA (sgRNA) and Cas9 protein required for editing to knock out the “don’t eat me signal” in macrophages that prevents phagocytosis of cancer cells. Turning off this signal increased the innate phagocytic capabilities of the macrophages by 4-fold. This improved attack and elimination of cancer cells makes this strategy promising for the creation of “weaponized” macrophages for cancer immunotherapy.Keywords
Funding Information
- NIH Office of the Director (EB022641, GM077173)
- Chemistry-Biology Interface Training Grant (5T32GM008515)
This publication has 27 references indexed in Scilit:
- Direct Delivery of Functional Proteins and Enzymes to the Cytosol Using Nanoparticle-Stabilized NanocapsulesACS Nano, 2013
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implicationsCurrent Opinion in Immunology, 2012
- Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcomaProceedings of the National Academy of Sciences, 2012
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences, 2012
- Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapyBlood, 2011
- CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destructionProceedings of the National Academy of Sciences, 2011
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic LeukemiaCancer Research, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Therapeutic antibodies: successes, limitations and hopes for the futureBritish Journal of Pharmacology, 2009
- Genetic engineering of T cells for adoptive immunotherapyImmunologic Research, 2008